智通财经APP获悉，罗氏(RHHBY.US)旗下基因泰克(Genentech)宣布，美国FDA已批准血栓溶解剂TNKase(tenecteplase)上市，用于治疗成人急性缺血性中风(AIS)。新闻稿指出，TNKase是FDA近30年来批准的首款中风药物。TNKase通过一次五秒的静脉推注给药，与同为罗氏开发的标准治疗Activase(先进行静脉推注，再进行60分钟输注)相比，这种给药方式更快速和便捷。
TNKase是一种组织纤溶酶原激活剂，具有溶解血栓的作用。TNKase以一次五秒的静脉推注给药，启动一种能够分解血栓成分纤维蛋白的生化反应。其最常见的不良反应为出血和过敏反应。研究结果显示，在急性缺血性中风患者中，TNKase在安全性和疗效方面与Activase相当。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.